Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

aTYR PHARMA (ATYR) EBITDA Margin (2019 - 2025)

aTYR PHARMA's EBITDA Margin history spans 6 years, with the latest figure at 14076.32% for Q3 2025.

  • For Q3 2025, EBITDA Margin changed N/A year-over-year to 14076.32%; the TTM value through Dec 2025 reached 40856.32%, down 1195674.0%, while the annual FY2025 figure was 40856.32%, 1195674.0% down from the prior year.
  • EBITDA Margin reached 14076.32% in Q3 2025 per ATYR's latest filing, down from 7079.15% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 76.55% in Q4 2022 to a low of 14076.32% in Q3 2025.
  • Average EBITDA Margin over 4 years is 6201.42%, with a median of 5326.4% recorded in 2024.